✦ LIBER ✦

Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial

✍ Scribed by Michael Berk; Clarissa S. Gama; Suresh Sundram; Harry Hustig; Les Koopowitz; Russell D'Souza; Hamish Malloy; Cate Rowland; Alison Monkhouse; Andrew Monkhouse; Fiona Bole; Sumathy Sathiyamoorthy; Danijela Piskulic; Seetal Dodd

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 78 KB
Volume: 24
Category: Article
ISSN: 0885-6222
DOI: 10.1002/hup.1017

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective

Schizophrenia is a multifaceted illness with positive, negative and cognitive symptom domains. Standard treatments often focus on positive symptoms and may not adequately relieve other symptoms. Previous studies have suggested a role for mirtazapine in schizophrenia, particularly in negative symptoms. This study investigates the efficacy of adding mirtazapine to treatment as usual to alleviate the negative symptoms of schizophrenia.

Methods

In a 6 week, double‐blind clinical trial, participants with a diagnosis of schizophrenia and currently being treated with atypical antipsychotic medication were randomised to adjunctive treatment with mirtazapine (30 mg/day) or placebo. The primary outcome measure was improvement in the Positive and Negative Syndrome Scale (PANSS). Measures of cognition, collected at baseline and week 6 only, were analysed using an Analysis of Covariance (ANCOVA) model. All other outcome measures were analysed using a linear mixed model.

Results

Forty participants were recruited to the study with equal numbers randomised to each treatment arm. There was no significant difference between mirtazapine and placebo treated participants for improvement in PANSS scores or any of the secondary outcome measures at any stage during the 6‐week trial.

Conclusions

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients

✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to

Efficacy of selegiline add on therapy to

Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study

✍ Afshar Amiri; Ahmad-Ali Noorbala; Ali-Akbar Nejatisafa; Abolfazl Ghoreishi; Moha 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB

## Abstract ## Objective It has been reported that selegiline, a Selective Monoamine Oxidase Inhibitor B (MAOI‐B), at low doses would be helpful for treating negative symptoms in schizophrenia. Nevertheless, the results are contradictory so far. This study was designed to investigate the effect of

Randomized, placebo-controlled, double-b

Randomized, placebo-controlled, double-blind clinical trial evaluating the treatment of plantar fasciitis with an extracoporeal shockwave therapy (ESWT) device: A North American confirmatory study

✍ Patricia Kudo; Katie Dainty; Michael Clarfield; Larry Coughlin; Pauline Lavoie; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 145 KB

## Abstract Despite numerous publications and clinical trials, the results of treatment of recalcitrant chronic plantar fasciitis with extracorporeal shockwave therapy (ESWT) still remain equivocal as to whether or not this treatment provides relief from the pain associated with this condition. The

Epitope-specific immunotherapy of rheuma

Epitope-specific immunotherapy of rheumatoid arthritis: Clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial

✍ Eva C. Koffeman; Mark Genovese; Diane Amox; Elissa Keogh; Ernesto Santana; Eric 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB 👁 2 views

Long-term efficacy and safety of zoledro

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors : A randomized, Phase III, double-blind, placebo-controlled trial

✍ Lee S. Rosen; David Gordon; N. Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB 👁 2 views

Tocilizumab inhibits structural joint da

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year

✍ Joel M. Kremer; Ricardo Blanco; Marek Brzosko; Ruben Burgos-Vargas; Anne-Marie H 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB 👁 3 views